Cargando…
Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain overcome antibody size and complexity while maintaining analogous binding loops. However, antibodies and their derivatives remain the gold standard for the design of new therapeutics. In response, clinical-stage th...
Autores principales: | Chandler, Peter G., Buckle, Ashley M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140400/ https://www.ncbi.nlm.nih.gov/pubmed/32143310 http://dx.doi.org/10.3390/cells9030610 |
Ejemplares similares
-
Mutational and biophysical robustness in a prestabilized monobody
por: Chandler, Peter G., et al.
Publicado: (2021) -
Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2
por: Park, Seung-Hwan, et al.
Publicado: (2015) -
Structural and dynamic properties that govern the stability of an engineered fibronectin type III domain
por: Porebski, Benjamin T., et al.
Publicado: (2015) -
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
por: Wojcik, John, et al.
Publicado: (2010) -
FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein
por: Miller, Christina J., et al.
Publicado: (2021)